ECSP044862A - Pirenzepine ophthalmic gel - Google Patents
Pirenzepine ophthalmic gelInfo
- Publication number
- ECSP044862A ECSP044862A EC2004004862A ECSP044862A ECSP044862A EC SP044862 A ECSP044862 A EC SP044862A EC 2004004862 A EC2004004862 A EC 2004004862A EC SP044862 A ECSP044862 A EC SP044862A EC SP044862 A ECSP044862 A EC SP044862A
- Authority
- EC
- Ecuador
- Prior art keywords
- ophthalmic gel
- pirenzepine
- pirenzepine ophthalmic
- gel
- pyrenzepine
- Prior art date
Links
- 229940100655 ophthalmic gel Drugs 0.000 title 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 title 1
- 229960004633 pirenzepine Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000001491 myopia Diseases 0.000 abstract 1
- 230000004379 myopia Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Es un objeto primario de la presente invención proporcionar una formulación oftálmica acuosa, para tratar la miopía, ésta formulación comprende la pirenzepina en combinación con un portador de gel, aceptable farmacéuticamente
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29373101P | 2001-05-25 | 2001-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP044862A true ECSP044862A (es) | 2004-03-23 |
Family
ID=23130330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004004862A ECSP044862A (es) | 2001-05-25 | 2004-01-23 | Pirenzepine ophthalmic gel |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040137069A1 (es) |
| EP (1) | EP1397132A4 (es) |
| JP (1) | JP2004531569A (es) |
| KR (1) | KR20040018380A (es) |
| CN (1) | CN1509172A (es) |
| BR (1) | BR0210013A (es) |
| CA (1) | CA2447562A1 (es) |
| EC (1) | ECSP044862A (es) |
| HU (1) | HUP0304071A2 (es) |
| IL (1) | IL158904A0 (es) |
| MX (1) | MXPA03010655A (es) |
| NO (1) | NO20035224D0 (es) |
| NZ (1) | NZ529615A (es) |
| PL (1) | PL366924A1 (es) |
| RU (1) | RU2297831C2 (es) |
| WO (1) | WO2002096418A1 (es) |
| ZA (1) | ZA200309791B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006008119A1 (en) * | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| JP4963359B2 (ja) * | 2005-01-12 | 2012-06-27 | ロート製薬株式会社 | 眼局所適用製剤 |
| EP2004172B1 (en) | 2006-03-31 | 2019-03-13 | Mati Therapeutics Inc. | Drug delivery structures and compositions for nasolacrimal system |
| US20100114309A1 (en) * | 2006-12-26 | 2010-05-06 | De Juan Jr Eugene | Drug delivery implants for inhibition of optical defects |
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| EP2008651A1 (en) | 2007-06-26 | 2008-12-31 | Drug Delivery Solutions Limited | A bioerodible patch |
| EP2207529B1 (en) | 2007-09-07 | 2014-12-31 | Mati Therapeutics Inc. | Drug cores for sustained release of therapeutic agents |
| WO2010083129A2 (en) | 2009-01-13 | 2010-07-22 | The Regents Of The University Of California | Implantable delivery vehicle for ocular delivery of muscarinic antagonists |
| HUE070784T2 (hu) * | 2010-10-25 | 2025-06-28 | Univ Manitoba | Terápiás készítmények diabéteszes szimmetrikus polineuropátia kezelésére |
| BR112013023458B1 (pt) * | 2011-03-14 | 2020-04-07 | Drug Delivery Solutions Ltd | composição oftálmica, e, método para fabricar a composição oftálmica |
| RU2635185C2 (ru) * | 2013-12-17 | 2017-11-09 | Иван Дмитриевич Захаров | Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| EP3302426A4 (en) | 2015-05-29 | 2018-12-05 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
| CN105663137A (zh) * | 2016-01-14 | 2016-06-15 | 王真 | 哌仑西平在制备治疗脓毒症疾病的药物中的应用 |
| KR102580933B1 (ko) * | 2016-05-25 | 2023-09-19 | 싱가포르 헬스 서비시즈 피티이 엘티디 | 아트로핀-함유 수성 조성물 |
| CA3205816A1 (en) | 2017-11-03 | 2019-05-09 | Alcon Inc. | Azabicyclo and diazepine derivatives for treating ocular disorders |
| EP3735209A4 (en) | 2018-01-05 | 2021-09-08 | University of Utah Research Foundation | TREATMENT OF THE PROGRESSION OF MYOPOIA |
| EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
| US20220273671A1 (en) * | 2019-03-26 | 2022-09-01 | Winsantor, Inc. | Topical formulations for treatment of peripheral neuropathies |
| KR20220018484A (ko) * | 2019-06-10 | 2022-02-15 | 제니비젼 인크. | 시력 장애를 치료하기 위한 방법 및 제형 |
| AU2020311441B2 (en) * | 2019-07-11 | 2025-12-04 | University Of Utah Research Foundation | Multi-agent ocular formulations and treatment methods |
| KR102808906B1 (ko) * | 2021-06-18 | 2025-05-19 | 대우제약 주식회사 | 고점도 점안제를 무균여과하는 방법 |
| CN117338787A (zh) * | 2023-11-24 | 2024-01-05 | 南京恒道医药科技股份有限公司 | 一种眼用药物组合物及其制备方法 |
| WO2025171327A1 (en) * | 2024-02-09 | 2025-08-14 | Levation Pharma Ltd. | Methods for producing dermatological gel compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU188852B (en) * | 1983-03-16 | 1986-05-28 | Richter Gedeon Vegyeszeti Gyar Rt,Hu | Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer |
| US4865599A (en) * | 1986-08-18 | 1989-09-12 | Houston Biotechnology, Inc. | Ophthalmic compositions for treating nerve degeneration |
| CA1336490C (en) * | 1988-06-03 | 1995-08-01 | Paul Michael Iuvone | Pharmacological treatment of ocular development |
| US5122522A (en) * | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
| US5360801A (en) * | 1989-06-21 | 1994-11-01 | The Trustees Of The University Of Pennsylvania | Pharmacological stimulation of eye growth |
| ES2136686T3 (es) * | 1989-06-21 | 1999-12-01 | Univ Pennsylvania | Tratamiento y control de desarrollo ocular con agonistas colinergicos. |
| US5055302A (en) * | 1990-02-22 | 1991-10-08 | Trustees Of The University Of Pennsylvania | Neuropeptide control of ocular growth |
| SU1827797A3 (ru) * | 1991-04-30 | 1996-05-20 | Н.Б. Леонидов | Лекарственный препарат для анестезии глаз |
| US5461808A (en) * | 1993-02-08 | 1995-10-31 | Fritts; Robert W. | Table top backlit display |
| US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
| US5461052A (en) * | 1993-04-30 | 1995-10-24 | The Trustees Of The University Of Pennsylvania | Prevention of myopia by tricyclic compounds |
| US5516808A (en) * | 1994-10-27 | 1996-05-14 | Sawaya; Assad S. | Topical cellulose pharmaceutical formulation |
| US5888493A (en) * | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
| RU2135129C1 (ru) * | 1998-11-18 | 1999-08-27 | Ларионов Евгений Викторович | Глазные капли "корнеалон-плюс" |
| US6164282A (en) * | 1999-01-27 | 2000-12-26 | Allergan Sales, Inc. | Methods for restoring and/or enhancing accommodation in pseudo phakia |
-
2002
- 2002-05-01 BR BR0210013-4A patent/BR0210013A/pt not_active IP Right Cessation
- 2002-05-01 CN CNA02810174XA patent/CN1509172A/zh active Pending
- 2002-05-01 JP JP2002592928A patent/JP2004531569A/ja not_active Withdrawn
- 2002-05-01 RU RU2003136735/15A patent/RU2297831C2/ru not_active IP Right Cessation
- 2002-05-01 PL PL02366924A patent/PL366924A1/xx not_active Application Discontinuation
- 2002-05-01 KR KR10-2003-7015393A patent/KR20040018380A/ko not_active Ceased
- 2002-05-01 WO PCT/US2002/013823 patent/WO2002096418A1/en not_active Ceased
- 2002-05-01 MX MXPA03010655A patent/MXPA03010655A/es not_active Application Discontinuation
- 2002-05-01 NZ NZ529615A patent/NZ529615A/en unknown
- 2002-05-01 HU HU0304071A patent/HUP0304071A2/hu unknown
- 2002-05-01 IL IL15890402A patent/IL158904A0/xx unknown
- 2002-05-01 EP EP02734130A patent/EP1397132A4/en not_active Withdrawn
- 2002-05-01 CA CA002447562A patent/CA2447562A1/en not_active Abandoned
-
2003
- 2003-10-31 US US10/698,320 patent/US20040137069A1/en not_active Abandoned
- 2003-11-24 NO NO20035224A patent/NO20035224D0/no not_active Application Discontinuation
- 2003-12-18 ZA ZA200309791A patent/ZA200309791B/xx unknown
-
2004
- 2004-01-23 EC EC2004004862A patent/ECSP044862A/es unknown
-
2006
- 2006-04-07 US US11/400,635 patent/US20060188576A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1397132A1 (en) | 2004-03-17 |
| JP2004531569A (ja) | 2004-10-14 |
| KR20040018380A (ko) | 2004-03-03 |
| WO2002096418A1 (en) | 2002-12-05 |
| MXPA03010655A (es) | 2007-06-22 |
| IL158904A0 (en) | 2004-05-12 |
| US20040137069A1 (en) | 2004-07-15 |
| NZ529615A (en) | 2005-07-29 |
| BR0210013A (pt) | 2004-08-10 |
| ZA200309791B (en) | 2004-10-04 |
| HUP0304071A2 (hu) | 2004-04-28 |
| US20060188576A1 (en) | 2006-08-24 |
| RU2003136735A (ru) | 2005-03-27 |
| CN1509172A (zh) | 2004-06-30 |
| EP1397132A4 (en) | 2006-12-13 |
| PL366924A1 (en) | 2005-02-07 |
| RU2297831C2 (ru) | 2007-04-27 |
| NO20035224D0 (no) | 2003-11-24 |
| CA2447562A1 (en) | 2002-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03010655A (es) | Gel oft??lmico de pirenzepina. | |
| EA200400481A1 (ru) | Применение флибансерина для лечения половых расстройств | |
| CY1117417T1 (el) | Νιτροοξυπαραγωγα προσταγλανδινης | |
| HN1999000015A (es) | Tratamiento para una disfuncion sexual femenina | |
| TR200102711T2 (tr) | Kriz halindeki başağrılarının iyileştirilmesinde kullanıma yönelik antikonvülsan türevler | |
| AU3831301A (en) | Method for treating ocular pain | |
| IS7215A (is) | Aðferðir til að meðhöndla nýæðarsjúkdóma í augum | |
| YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
| AR021643A1 (es) | Combinacion de cerivastatina y fibratos. | |
| TR200000755T2 (tr) | Karşıt olma-karşı gelme bozukluğunun tedavisi. | |
| EA200300929A1 (ru) | Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv | |
| NO20053042L (no) | Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi. | |
| DK1097173T3 (da) | Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler | |
| BR0318278A (pt) | compostos de éter aminocicloexìlico e usos dos mesmo | |
| DE60331638D1 (de) | Keratin-netzwerke enthaltende wundverbände für gewebedefekte | |
| CY1106409T1 (el) | Παραγωγα κινολινης | |
| EE05357B1 (et) | Tablett, mis sisaldab vhemalt kahte eristatavat segmenti, ning selle kasutamine | |
| WO2005013911A3 (en) | Protective and therapeutic uses for tocotrienols | |
| EA200300727A1 (ru) | Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции | |
| CR7198A (es) | Tableta que contiene cetirizina y pseudoefedrina | |
| TR200103125T2 (tr) | Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri. | |
| EA200601238A1 (ru) | Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела | |
| BR0010699A (pt) | Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários | |
| ITMI20021860A1 (it) | Impiego dei triptani come agenti antivirali. | |
| MY141606A (en) | N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa |